Cutting-edge patents in Alzheimer's disease drug discovery: Anticipation of potential future treatments

Recent Patents on CNS Drug Discovery

Volumn 2, Issue 2, 2007, Pages 113-123

  Lecanu, Laurent ^a   Papadopoulos, Vassilios ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid binding; Glycogen synthase kinase 3; Metal chelators; Secretase; Treatment; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID PROTEIN; BETA SECRETASE INHIBITOR; CAPROSPINOL; CHOLINESTERASE INHIBITOR; COUMARINYL BIARYLPIPERAZINE; CURCUMIN; DONEPEZIL; EPIGALLOCATECHIN GALLATE; EPITOPE; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; IMMUNOGLOBULIN; JMV 2764; KMI 358; KMI 370; KMI 429; MACROCYCLIC PEPTIDOMIMETIC AGENT; MACROHETEROBICYCLIC PEPTIDOMIMETIC AGENT; MRK 560; NAPHTHYLBIARYLPIPERAZINE; OM 99; OM 99 2; PEPTIDE ANTIBODY; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUNTINGTON CHOREA; IC 50; LIVER TOXICITY; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATENT; PRIORITY JOURNAL; REVIEW; STROKE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CALMODULIN-BINDING PROTEINS; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNIZATION; PATENTS AS TOPIC;

EID: 34250727624     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488907780832715     Document Type: Review

References (151)

1. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57(3): 489-495.
2. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363(9427): 2105-2115.
3. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; (3): CD003154.
4. Huey ED, Dustin IH, Overman GP, Mirza N, Sunderland T. Development of subtle psychotic symptoms with memantine: a case report. J Clin Psychiatry 2005; 66(5): 658-659.
5. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8(8): 1051-1058.
6. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26(1): 27-35.
7. Lecanu L, Greeson J, Papadopoulos V. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology 2006; 76(1): 19-33.
8. Yang LB, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003; 9(1): 3-4.
9. Li R, Lindholm K, Yang LB, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004; 101(10): 3632-3637.
10. Laird FM, Cai H, Savonenko AV, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta, amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005; 25(50): 11693-11709.
11. Ohno M, Chang L, Tseng W, et al. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 2006; 23(1): 251-260.
12. Bruinzeel W, Yon J, Giovannelli S, Masure S. Recombinant insect cell expression and purification of human beta-secretase (BACE-1) for X-ray crystallography. Protein Expr Purif 2002; 26(1): 139-148.
13. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000; 290(5489): 150-153.
14. Hong L, Turner RT, III, Koelsch G, Shin D, Ghosh AK, Tang J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM003. Biochemistry 2002; 41(36): 10963-10967.
15. Hong L, He X, Huang X, Chang W, Tang J. Structural features of human memapsin 2 (beta-secretase) and their biological and pathological implications. Acta Biochim Biophys Sin (Shanghai) 2004; 36(12): 787-792.
16. Turner RT, III, Koelsch G, Hong L, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 2001; 40(34): 10001-10006.
17. Tang, J., Xinli, L., Koelsch, G., Hong, L.: US20036545127 (2003).
18. Ghosh AK, Bilcer G, Harwood C, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 2001; 44(18): 2865-2868.
19. Hom RK, Fang LY, Mamo S, et al. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 2003; 46(10): 1799-1802.
20. Kiso, Y.: US 20070004637 A1 (2007).
21. Asai M, Hattori C, Iwata N, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96(2): 533-540.
22. Kimura T, Shuto D, Kasai S, et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004; 14(6): 1527-1531.
23. Chang WP, Koelsch G, Wong S, et al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 2004; 89(6): 1409-1416.
24. Lefrano-Jullien S, Lisowski V, Hernandez JF, Martinez J, Checler F. Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. Br J Pharmacol 2005; 145(2): 228-235.
25. Coburn, C.A., Stachel, S.J., Vacca, J.P.: US20060058278A1 (2006).
26. Pulley, S.R., Beck, J.P., Ten Brink, R.E., Jacobs, J.S.: US20067067507 (2006).
27. Hanessian S, Yang G, Rondeau JM, Neumann U, Betachart C, Tintelmot-Blomley M. Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease beta-site amyloid precursor protein cleaving enzyme (BACE). J Med Chem 2006; 49(15): 4544-4567.
28. Stachel SJ, Coburn CA, Sankaranarayanan S, et al. Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem 2006; 49(21): 6147-6150.
29. Ghosh AK, Devasamudram T, Hong L, et al. Stucture-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg Med Chem Lett 2005; 15(1): 15-20.
30. Garino C, Tomita T, Pietrancosta N, et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assay. J Med Chem 2006; 49(14): 4275-4285.
31. McSwinggen, J., Beigelman, L.L.P.: US20050209179A1 (2005).
32. Singer O, Marr RA, Rockenstein E. et al. Targeting BACB1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8(10): 1343-1349.
33. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001; 4(3): 233-234.
34. Luo Y, Bolon B, Kahn S. et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4(3): 231-232.
35. Luo Y, Bolon B, Damore MA, et al. BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003; 14(1): 81-88.
36. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10(12): 1317-1324.
37. Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analyses of B. J Biol Chem 2005; 280(35): 30797-30806.
38. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003; 5(5): 486-488.
39. Sato C, Morohashi Y, Tomita T, Iwatsubo, T. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci 2006; 26(46): 12081-12088.
40. Yamasaki A, Eimer S, Okochi M, et al. The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase. J Neurosci 2006; 26(14): 3821-3828.
41. De SB, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391(6665): 387-390.
42. Collins, I.J., Cooper, L.C.: US20077157478 (2007).
43. Josien, H.B., Clader, J.W., Asberom, T., Pissanitski, D.A.: US20067122675 (2006).
44. Pineiro, J.L.C., Hannam, J.C., Harrisson, T., Madin, A., Ridgill, M.P.: US20050182111A1 (2005).
45. Churcher, I, Harrison, T., Kerrad, S., Oakley, P.J, Shaw, D.E., Teall, M.R., Williams, S.: US20067101895 B2 (2006).
46. Lanz TA, Hosley JD, Adams WJ, Merchant KM. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6- oxo-6,7-dihydro-5H-dibenzo [b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 2004; 309(1): 49-55.
47. Tsai JY, Wolfe MS, Xia W. The search for gamma-secretase and development of inhibitors. Curr Med Chem 2002; 9(11): 1087-1106.
48. Geling A. Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002; 3(7): 688-694.
49. Kitzmann M, Bonnieu A, Duret C, et al. Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. J Cell Physiol 2006; 208(3): 538-548.
50. Hadland BK, Manley NR, Su D, et al. Gamma-secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 2001; 98(13): 7487-7491.
51. Wang XD, Leow CC, Zha J, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol. 2006; 290(1): 66-80.
52. Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/ gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem 2005; 280(24): 23251-23261.
53. Hass IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem 2005; 280(10): 9313-9319.
54. Cowan JW, Wang X, Guan R, et al. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J Biol Chem 2005; 280(19): 19331-19342.
55. Lai C, Feng L. Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes. Biochem Biophys Res Commun 2004; 314(2): 535-542.
56. Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42(1): 23-36.
57. Shen J, Kelleher RJ, III. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 2007; 104(2): 403-409.
58. Best JD, Smith DW, Reilly MA, et al. The novel {gamma} secretase inhibitor MRK-560 reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2006.
59. Frangione, B., Wisniewski, T., Sigurdsson, E.M.: US20046713450 B2 ( 2004).
60. Schenk, D.: US20046787138 B1 (2004).
61. Schenk, D.: US20056905686 (2005).
62. Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005; 25(40): 9096-9101.
63. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization. (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553-1562.
64. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61(1): 46-54.
65. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8(11): 1270-1275.
66. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8(11): 1263-1269.
67. Wang, C.Y.: US20056906169B2 (2005).
68. Schenk, D., Bard, F., Yednock, T.: US20046750324B1 (2004).
69. Schenk, D.: US20046787637B1 (2004).
70. Schenk, D.: US20056913745 (2005).
71. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75(10): 1472-1474.
72. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000; 924: 17-25.
73. Modler AJ, Gast K, Lutsch G, Damaschun G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J Mol Biol 2003; 325(1): 135-148.
74. Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 2006; 6(6): 597-608.
75. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41(5): 345-352.
76. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277(35): 32046-32053.
77. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95(11): 6448-6453.
78. Tjernberg LO, Lilliehook C, Callaway DJ, et al. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 1997; 272(19): 12601-12605.
79. Nordstedt, C., Naslund, J., Thyberg, J., Tjernberg, L.O., Terenius, L.: US20016331440 (2001).
80. Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 2006; 45(32): 9906-9918.
81. Gibson TJ, Murphy RM. Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context. Biochemistry 2005; 44(24): 8898-8907.
82. Kim JE, Lee M. Fullerene inhibits beta-amyloid peptide aggregation. Biochem Biophys Res Commun 2003; 303(2): 576-579.
83. Parker MH, Chen R, Conway KA, et al. Synthesis of (-)-5,8-dihydroxy-3R- methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthale ne: an inhibitor of beta-amyloid(1-42) aggregation. Bioorg Med Chem 2002; 10(11): 3565-3569.
84. Kisilevsky, R., Szarek, W., Weaver, D.: US19995972328 (1999).
85. Liu D, Xu Y, Feng Y, et al. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry 2006; 45(36): 10963-10972.
86. Castillo, G.M., Choi, P.Y., Cummings, J.A., Nguyen, B.P., Snow, A.D.: US2002015106A1 (2002).
87. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 2006; 23(1): 55-64.
88. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280(7): 5892-5901.
89. Kim, D.S.H.L.: US20056887898B1 (2005).
90. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29(2): 47-56.
91. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997; 31(6): 645-655.
92. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 2001; 889(1-2): 181-190.
93. Yao, Z.X., Lecanu, L., Teper, G., Greeson, J., Papadopoulos, V.: US20060009433A1 (2007).
94. Teper GL, Lecanu L, Greeson J, Papadopoulos V. Methodology for multi-site ligand-protein docking identification developed for the optimization of spirostenol inhibition of beta-amyloid-induced neurotoxicity. Chem Biodivers 2005; 2(11): 1571-1579.
95. Tillement L, Lecanu L, Yao W, Greeson J, Papadopoulos V. The spirostenol (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate blocks mitochondrial uptake of Abeta in neuronal cells and prevents Abeta-induced impairment of mitochondrial function. Steroids 2006; 71(8): 725-735.
96. Lecanu L, Yao W, Teper GL, Yao ZX, Greeson J, Papadopoulos V. Identification of naturally occurring spirostenols preventing beta-amyloid-induced neurotoxicity. Steroids 2004; 69(1): 1-16.
97. Dixon R, Furutachi T, Lieberman S. The isolation of crystalline 22R-hydroxycholesterol and 20 alpha, 22R-dihydroxycholesterol from bovine adrenals. Biochem. Biophys Res Commun 1970; 40(1): 161-165.
98. Yao ZX, Brown RC, Teper G, Greeson J, Papadopoulos V. 22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytonixicity by binding to beta-amyloid peptide. J Neurochem 2002; 83(5): 1110-1119.
99. Gouras GK, Tsai J, Naslund J. et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000; 156(1): 15-20.
100. Gyure KA. Durham R, Stewart WF, Smialek JE, Tronceso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 2001; 125(4): 489-02.
101. McGeer PL, Akiyama, H, Kawamata T, Yamada T, Walker DG, Ishii T. Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy. J Neurosci Res 1992; 31(3): 428-442.
102. Takahashi RH, Milner TA, Li F, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is asociated with synaptic pathology. Am J Pathol 2002; 161(5): 1869-1979.
103. Lecanu L, Sidahmed El-K, Greeson J, Papadopapoulos V. Caprospinol improves brain histopathology and recovers memory function in a rat model of Alzheimers disease.; in 8th International Conferece AD/PD 2007, Salzburg, Austria. 2007, vol Salzburg, Austria.
104. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD001190.
105. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1): CD005593.
106. Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 2006; 20(4): 311-325.
107. Orgogozo JM, Small GW, Hammond G, Van BB, Schwalen S. Effects of galantamine in patients with mild Alzheimer's disease. Curr Med Res Opin 2004; 20(11): 1815-1920.
108. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 Years Int J Clin Pract 2005; 59(4): 473-477.
109. Bullock R, Touchon I, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21(8): 1317-1527.
110. Winblad B, Wimo A, Engedal K, et al. 3-year study of donapezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Gariatr Cogn Disord 2006; 21(5-6): 353-363.
111. Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet 2004; 363(9427): 2100-2101.
112. Kaduszkiewicz H, Beck-Bornholdt HP, van den BH, Zimmermann T. [Doubtful evidence for the me of the cholinesterase inhibitor donepezil in patients with dementia-a. systematic review]. Fortschr Neurol Psychiatr 2004; 72(10): 557-563.
113. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den BH. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331(7512): 321-327.
114. Licht D., Lovinger, I., Caciularu, F., Gilbert, A.: US20070189685A1 ( 2007).
115. Maruyama W, Weinstock M, Youdim MB. Nagai M, Naoi M. Anti-apoptotic action of anti-Alzheimer's drug, TV3326 [(N-propargy])-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003; 341(3): 233-236.
116. Weinstock M, Bejar C, Wang RH, et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm Suppl 2000; (60): 157-169.
117. Buccafusco JJ, Terry AV Jr, Goren T, Blaugrun E. Potential cognitive actions of (N-propargly-(3R)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 2003; 119(3): 669-678.
118. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 2006; 20(12): 2177-2179.
119. Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 2003; 993: 378-386.
120. Bartorelli L, Giraldi C, Saccardo M, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21(11): 1809-1818.
121. Rampa A, Piazzi L, Belluti F, et al. Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl) methyl]aminoalkoxyaryl derivatives. J Med Chem 2001; 44(23): 3810-3820.
122. Schott Y, Decker M, Rommelspacher H, Lehmann J. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 2006; 16(22): 5840-5843.
123. Belluti F, Rampa A, Piazzi L, et al. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 2005; 48(13): 4444-4456.
124. Munoz-Ruiz P, Rubio L, Garcia-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 2005; 48(23): 7223-7233.
125. Li J, Huang H, Miezan Ezoulin JM, et al. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Int J Neuropsychopharmacol 2006; 1-9.
126. Papadopoulos, V., Lecanu, L., Greeson, J.: US20060247248A1 (2006).
127. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 2000; 920: 321-327.
128. Lecanu L, Tillement L, McCourty A., Yao W., Piechot A., Greeson J, Tzalis D., Papadopoulos V. Synthesis and biological evaluation of dimethyl-carbamic acid 2,3-bis-dimethylcarbamoyloxy-6-(4-ethyl-piperazine-1-carbonyl)-phenyl ester: a multi-target therapeutic approach to neuroprotection; in 2006.
129. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 2005; 146(8): 1041-1059.
130. Becaria A, Bondy SC, Campbell A. Aluminum and copper interact in the promotion of oxidative but not inflammatory events: implications for Alzheimer's disease. J Alzheimers Dis 2003; 5(1): 31-38.
131. Lynch T, Chemy RA, Bush AI. Oxidative processes in Alzheimer's disease: the role of abeta-metal interactions. Exp Gerontol 2000; 35(4): 445-451.
132. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996; 143(1-2): 137-142.
133. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158(1): 47-52.
134. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci 2000; 920: 292-304.
135. Moret V, Laras Y, Pietrancosta N, et al. 1,1′-Xylyl bis-1,4,8,11 -tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg Med Chem Lett 2006; 16(12): 3298-3301.
136. Huang, X.: US20040204344A1 (2004).
137. Dedeoglu A, Cormier K, Payton S, et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39(11-12): 1641-1649.
138. Striem, S., Friedman, J.E., Reznitsky-Cohen, D., Kozak, A.: US20060167092A1 (2006).
139. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004; 25(10): 1315-1321.
140. Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005; 126(2): 317-326.
141. Youdim, M.B., Fridkin, M., Zheng, H., Warshawsky A.: US20060234927A1 ( 2006).
142. Ghribi O, Herman MM, Savory J. Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J Neurosci Res 2003; 71(6): 853-862.
143. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102(19): 6990-6995.
144. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116(Pt 7): 1175-1186.
145. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147(1): 58-62.
146. Cochran, J., Nanthakumar, S., Harrington, E., Wang, J.: US20046762179B2 (2004).
147. Garcia, A.A., Ando, R., Arimoto, K., Uchara, F., Li, A.T., Shoda, A., Reid, J., Watanabe, K.: US20056844335B2 (2005).
148. Nuss, J.M., Ramurthy, S.: US20056949547B2 (2005).
149. Nuss, J.M., Harrison, S.D., Ring, D.B., Boyce, R.S, Johnson, K., Pfister, K.B., Ramurthy, S., Seely, L., Wagman, A.S., Manoj, C.D., Levine, B.H.: US20067045519B2 (2006).
150. Wagman, A.S., Subramanian, S., Nuss, J.M.: US20066989382B2 (2006).
151. Kelly S, Zhao H, Hua SG, et al. Glycogen synthase, kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp Neurol 2004; 188(2): 378-386.